TY - JOUR
T1 - Association of CD44 isoform immunohistochemical expression with myometrial and vascular invasion in endometrioid endometrial carcinoma
AU - Stokes, Gary N.
AU - Shelton, Jack B.
AU - Zahn, Christopher M.
AU - Kendall, Brian S.
PY - 2002
Y1 - 2002
N2 - Objective. Appropriate clinical management of cases of FIGO Grade I and II endometrial carcinoma relies heavily on the determination of myometrial invasion (MI). There are no reports addressing expression of the cell adhesion molecule CD44 in the subset of Grade I and II endometrioid carcinoma (EC) as it relates to prognosis, including MI. Methods. Immunohistochemical staining for CD44s and CD44v6 was evaluated in 40 hysterectomy specimens with Grade I and II EC, including 11 noninvasive ECs, 14 with MI <50% of myometrial thickness, and 15 with deep invasion (MI >50%). Staining characteristics according to the presence of MI and vascular space invasion (VSI) were evaluated. Strong membranous staining of > 10% of tumor cells was interpreted as positive. Results. CD44v6 staining was positive in 20% (8/40) of cases, including 45% (5/11) of EC without MI but only 10% (3/29) with MI (P = 0.025). CD44v6 staining was not present in deeply invasive tumors (0/15), while it was present in 8/25 superficially or noninvasive tumors (P = 0.016). Sensitivity and specificity were 25 and 100%, respectively, using CD44v6 in evaluating deep myometrial invasion. CD44s showed a trend toward positive staining when comparing noninvasive versus invasive tumors and noninvasive/superficially invasive versus deeply invasive tumors (P = 0.08 and 0.12, respectively). CD44s or CD44v6 staining was highly specific for absence of VSI, although statistical comparison did not reach significance. Conclusion. Deeply invasive EC was associated with a consistent lack of CD44v6 expression. This may have potential clinical utility if this finding is demonstrated in further Study of prehysterectomy sampling specimens containing Er.
AB - Objective. Appropriate clinical management of cases of FIGO Grade I and II endometrial carcinoma relies heavily on the determination of myometrial invasion (MI). There are no reports addressing expression of the cell adhesion molecule CD44 in the subset of Grade I and II endometrioid carcinoma (EC) as it relates to prognosis, including MI. Methods. Immunohistochemical staining for CD44s and CD44v6 was evaluated in 40 hysterectomy specimens with Grade I and II EC, including 11 noninvasive ECs, 14 with MI <50% of myometrial thickness, and 15 with deep invasion (MI >50%). Staining characteristics according to the presence of MI and vascular space invasion (VSI) were evaluated. Strong membranous staining of > 10% of tumor cells was interpreted as positive. Results. CD44v6 staining was positive in 20% (8/40) of cases, including 45% (5/11) of EC without MI but only 10% (3/29) with MI (P = 0.025). CD44v6 staining was not present in deeply invasive tumors (0/15), while it was present in 8/25 superficially or noninvasive tumors (P = 0.016). Sensitivity and specificity were 25 and 100%, respectively, using CD44v6 in evaluating deep myometrial invasion. CD44s showed a trend toward positive staining when comparing noninvasive versus invasive tumors and noninvasive/superficially invasive versus deeply invasive tumors (P = 0.08 and 0.12, respectively). CD44s or CD44v6 staining was highly specific for absence of VSI, although statistical comparison did not reach significance. Conclusion. Deeply invasive EC was associated with a consistent lack of CD44v6 expression. This may have potential clinical utility if this finding is demonstrated in further Study of prehysterectomy sampling specimens containing Er.
KW - CD44v6
KW - Cell adhesion molecule
KW - Endometrial carcinoma
KW - Invasion
KW - Uterus
UR - http://www.scopus.com/inward/record.url?scp=0036141149&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036141149&partnerID=8YFLogxK
U2 - 10.1006/gyno.2001.6470
DO - 10.1006/gyno.2001.6470
M3 - Article
AN - SCOPUS:0036141149
SN - 0090-8258
VL - 84
SP - 58
EP - 61
JO - Gynecologic Oncology
JF - Gynecologic Oncology
IS - 1
ER -